Helix BioPharma is a biopharmaceutical company specializing in the field of cancer therapy. The Company is developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's clinical product development initiatives include Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus. Helix is also developing its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma.